drugset
drugset / Trial / NCT00835497

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

NCT00835497 ↗

Phase 1 Completed 40 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA Pharmaceuticals USA with that of 5 mg/500 mg METAGLIP™ Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult subjects administered under fasting conditions.

Timeline

Start
2004-06
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Glipizide Small molecule 5 mg Oral
Subject Metformin Small molecule 500 mg Oral

Indications

No indication recorded.